Eudaimonia Partners’s 9 Meters Biopharma NMTR Stock Holding History

Eudaimonia Partners’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8	Closed	–	–	1461
2021 Q1	$0	Buy	+8	New	+$246	﹤0.01%	1672

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eudaimonia Partners's NMTR Position: Q2 2021 in Review

Eudaimonia Partners sold out of 9 Meters Biopharma (NMTR) in Q2 2021, closing a stake of 8 shares.

Eudaimonia Partners first reported a position in NMTR in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

Eudaimonia Partners reported no remaining 9 Meters Biopharma position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 8 9 Meters Biopharma shares in Q2 2021.
Eudaimonia Partners first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's 9 Meters Biopharma position peaked at $0 in Q1 2021.
99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.